Sonnet BioTherapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			9 Months Ended	12 Months Ended
	Aug. 31, 2024	Apr. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2025	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 EUR (€)	Apr. 30, 2023 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Acquired in-process research					$ 12,000	$ 12,000
Discovery Collaboration Agreements [Member]
Loss Contingencies [Line Items]
License fees					0	0
Discovery Collaboration Agreements [Member] \| XOMA [Member]
Loss Contingencies [Line Items]
MilestonePayments										$ 3,800,000
Discovery Collaboration Agreements [Member] \| XOMA [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees		$ 500,000			0	0
Alkem Agreement [ Member]
Loss Contingencies [Line Items]
MilestonePayments					1,000,000.0
License fees					100,000
Cellca Agreement [Member]
Loss Contingencies [Line Items]
MilestonePayments					600,000
Description of milestone payments				The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
MilestonePayments									$ 700,000
Payment for annual license fee obligation					600,000
Cellca Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation					100,000
Cellca Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees					0	0
Commercial product license fee		$ 100,000
The Brink Agreement [Member]
Loss Contingencies [Line Items]
License fees					12,000	12,000
Commercial product license fee					100,000
Annual license fee								$ 12,000
Cell line storage fee					12,000
The Brink Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Development license fee					100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
License fees						0
Payment for annual license fee obligation					100,000		€ 0.1
InvivoGen Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees					100,000
ProteoNic Agreement [Member]
Loss Contingencies [Line Items]
MilestonePayments					200,000		€ 0.2
License fees					0
SOC Agreement [Member]
Loss Contingencies [Line Items]
Agreements description	Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur, payable to the SOC, a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third party partnership.
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member]
Loss Contingencies [Line Items]
MilestonePayments			$ 1,000,000.0		0	0
Acquired in-process research			100,000
Evaluation milestone recognized			$ 300,000
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
License fees					$ 0	$ 0